JP2017522908A - セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法 - Google Patents

セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法 Download PDF

Info

Publication number
JP2017522908A
JP2017522908A JP2017525327A JP2017525327A JP2017522908A JP 2017522908 A JP2017522908 A JP 2017522908A JP 2017525327 A JP2017525327 A JP 2017525327A JP 2017525327 A JP2017525327 A JP 2017525327A JP 2017522908 A JP2017522908 A JP 2017522908A
Authority
JP
Japan
Prior art keywords
cfdna
tissue
nucleosome
cell type
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017525327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522908A5 (enExample
Inventor
ジェイ シェンデュア
ジェイ シェンデュア
マシュー スナイダー
マシュー スナイダー
マーティン キルヒャー
マーティン キルヒャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2017522908A publication Critical patent/JP2017522908A/ja
Publication of JP2017522908A5 publication Critical patent/JP2017522908A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Bioethics (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Software Systems (AREA)
  • Cell Biology (AREA)
  • Primary Health Care (AREA)
  • Signal Processing (AREA)
  • Oncology (AREA)
JP2017525327A 2014-07-25 2015-07-27 セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法 Pending JP2017522908A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462029178P 2014-07-25 2014-07-25
US62/029,178 2014-07-25
US201462087619P 2014-12-04 2014-12-04
US62/087,619 2014-12-04
PCT/US2015/042310 WO2016015058A2 (en) 2014-07-25 2015-07-27 Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020203304A Division JP2021045161A (ja) 2014-07-25 2020-12-08 セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法

Publications (2)

Publication Number Publication Date
JP2017522908A true JP2017522908A (ja) 2017-08-17
JP2017522908A5 JP2017522908A5 (enExample) 2018-09-06

Family

ID=55163988

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017525327A Pending JP2017522908A (ja) 2014-07-25 2015-07-27 セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法
JP2020203304A Pending JP2021045161A (ja) 2014-07-25 2020-12-08 セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法
JP2023082794A Active JP7681641B2 (ja) 2014-07-25 2023-05-19 セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020203304A Pending JP2021045161A (ja) 2014-07-25 2020-12-08 セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法
JP2023082794A Active JP7681641B2 (ja) 2014-07-25 2023-05-19 セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法

Country Status (8)

Country Link
US (4) US20170211143A1 (enExample)
EP (2) EP3172341A4 (enExample)
JP (3) JP2017522908A (enExample)
KR (2) KR102441391B1 (enExample)
CN (2) CN107002122B (enExample)
AU (2) AU2015292311B2 (enExample)
CA (1) CA2956208C (enExample)
WO (1) WO2016015058A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531016A (ja) * 2018-07-23 2021-11-18 ザ チャイニーズ ユニバーシティ オブ ホンコン 無細胞ｄｎａ損傷分析およびその臨床応用
JP2022517456A (ja) * 2019-01-24 2022-03-09 イルミナ インコーポレイテッド 臓器健康および疾患をモニタリングするための方法およびシステム

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260753B2 (en) 2011-03-24 2016-02-16 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
PL2893040T3 (pl) 2012-09-04 2019-05-31 Guardant Health Inc Sposoby wykrywania rzadkich mutacji i wariantu liczby kopii
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
CN111534580B (zh) 2013-12-28 2024-06-04 夸登特健康公司 用于检测遗传变异的方法和系统
TWI758011B (zh) 2014-07-18 2022-03-11 香港中文大學 Ｄｎａ混合物中之組織甲基化模式分析
CN107002122B (zh) * 2014-07-25 2023-09-19 华盛顿大学 确定导致无细胞dna的产生的组织和/或细胞类型的方法以及使用其鉴定疾病或紊乱的方法
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
WO2016123698A1 (en) * 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
DK3256605T3 (da) 2015-02-10 2022-03-14 Univ Hong Kong Chinese Påvisning af mutationer til cancerscreening og føtal analyse
US10453556B2 (en) 2015-07-23 2019-10-22 The Chinese University Of Hong Kong Analysis of fragmentation patterns of cell-free DNA
EP4180532A1 (en) * 2015-11-09 2023-05-17 Roche Molecular Systems, Inc. Methods for determining the origin of dna molecules
SG11201805119QA (en) 2015-12-17 2018-07-30 Guardant Health Inc Methods to determine tumor gene copy number by analysis of cell-free dna
US11514289B1 (en) * 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
ES2967443T3 (es) * 2016-07-06 2024-04-30 Guardant Health Inc Procedimientos de perfilado de fragmentoma de ácidos nucleicos sin células
CN109563543B (zh) 2016-07-15 2022-08-30 加利福尼亚大学董事会 产生核酸库的方法
US11788135B2 (en) 2016-08-05 2023-10-17 The Broad Institute, Inc. Methods for genome characterization
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
EP3792922A1 (en) 2016-09-30 2021-03-17 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
US20200048711A1 (en) 2016-10-12 2020-02-13 Bellwether Bio, Inc Determining cell type origin of circulating cell-free dna with molecular counting
EP4209598A1 (en) 2016-10-19 2023-07-12 The Chinese University of Hong Kong Gestational age assessment by methylation and size profiling of maternal plasma dna
TWI797095B (zh) 2016-10-24 2023-04-01 美商格瑞爾有限責任公司 腫瘤檢測之方法及系統
IL266347B2 (en) 2016-11-30 2025-01-01 Univ Hong Kong Chinese Analysis of cell-free DNA in urine and other samples
US20190309374A1 (en) * 2016-12-13 2019-10-10 Bellwether Bio, Inc. Determining a physiological condition in an individual by analyzing cell-free dna fragment endpoints in a biological sample
IL302912A (en) 2016-12-22 2023-07-01 Guardant Health Inc Methods and systems for analyzing nucleic acid molecules
WO2018132518A1 (en) 2017-01-10 2018-07-19 Juno Therapeutics, Inc. Epigenetic analysis of cell therapy and related methods
WO2018137685A1 (en) 2017-01-25 2018-08-02 The Chinese University Of Hong Kong Diagnostic applications using nucleic acid fragments
US11535896B2 (en) 2017-05-15 2022-12-27 Katholieke Universiteit Leuven Method for analysing cell-free nucleic acids
EP3635133B1 (en) * 2017-06-09 2026-08-05 Bellwether Bio, Inc. Determination of cancer type in a subject by probabilistic modeling of circulating nucleic acid fragment endpoints
EP3635134A4 (en) * 2017-06-09 2021-03-03 Bellwether Bio, Inc. DIAGNOSTIC CANCER OR OTHER PHYSIOLOGICAL CONDITIONS USING CIRCULATING NUCLEIC ACID FRAGMENT SENTINEL END POINTS
AU2018301704A1 (en) 2017-07-14 2020-03-05 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
WO2019020057A1 (en) 2017-07-26 2019-01-31 The Chinese University Of Hong Kong ENHANCING CANCER SCREENING WITH ACELLULAR VIRAL NUCLEIC ACIDS
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
CN107545153B (zh) * 2017-10-25 2021-06-11 桂林电子科技大学 一种基于卷积神经网络的核小体分类预测方法
CN111386362B (zh) * 2017-11-27 2024-11-12 深圳华大生命科学研究院 一种体液游离dna的文库构建方法及其应用
CN108061794B (zh) * 2017-12-25 2020-03-27 苏州大学 一种无染色、无探针、无损检测细胞或类细胞结构微生物的类型及其周期的方法
US12590326B2 (en) 2018-01-10 2026-03-31 Guardant Health, Inc. Methods for fragmentome profiling of cell-free nucleic acids
US11584929B2 (en) 2018-01-12 2023-02-21 Claret Bioscience, Llc Methods and compositions for analyzing nucleic acid
CN112119166B (zh) * 2018-03-13 2025-08-22 耶路撒冷希伯来大学伊萨姆研发有限公司 无细胞dna染色质免疫沉淀的诊断应用
CA3302676A1 (en) 2018-04-02 2026-05-13 Grail, Inc. Methylation markers and targeted methylation probe panels
WO2019209884A1 (en) 2018-04-23 2019-10-31 Grail, Inc. Methods and systems for screening for conditions
CN120608151A (zh) * 2018-05-18 2025-09-09 约翰·霍普金斯大学 用于评估和/或治疗癌症的无细胞dna
US20190385700A1 (en) * 2018-06-04 2019-12-19 Guardant Health, Inc. METHODS AND SYSTEMS FOR DETERMINING The CELLULAR ORIGIN OF CELL-FREE NUCLEIC ACIDS
WO2019236726A1 (en) 2018-06-06 2019-12-12 The Regents Of The University Of California Methods of producing nucleic acid libraries and compositions and kits for practicing same
CN108796056A (zh) * 2018-06-28 2018-11-13 元码基因科技（北京）股份有限公司 基于游离dna的目标基因捕获技术进行组织溯源的方法
WO2020006369A1 (en) * 2018-06-29 2020-01-02 Guardant Health, Inc. Methods and systems for analysis of ctcf binding regions in cell-free dna
CN108913682A (zh) * 2018-07-05 2018-11-30 上海奥测医疗科技有限公司 一种制备cfDNA参考品的方法
CN109448783B (zh) * 2018-08-07 2022-05-13 清华大学 一种染色质拓扑结构域边界的分析方法
EP3856903A4 (en) 2018-09-27 2022-07-27 Grail, LLC METHYLATION MARKER AND TARGETED METHYLATION PROBE PANEL
EP3815005A4 (en) * 2018-10-08 2022-03-30 Freenome Holdings, Inc. Transcription factor profiling
CN111172263A (zh) * 2018-11-12 2020-05-19 北京医院 一种应用于无创产前检测的参考物质及其制备方法
WO2020106987A1 (en) * 2018-11-21 2020-05-28 Karius, Inc. Detection and prediction of infectious disease
WO2020131872A1 (en) 2018-12-17 2020-06-25 Guardant Health, Inc. Determination of a physiological condition with nucleic acid fragment endpoints
CN113366122B (zh) * 2018-12-19 2024-01-12 香港中文大学 游离dna末端特征
US11657897B2 (en) * 2018-12-31 2023-05-23 Nvidia Corporation Denoising ATAC-seq data with deep learning
EP4567131A3 (en) 2019-01-31 2025-09-03 Guardant Health, Inc. Compositions and methods for isolating cell-free dna
CN109841265B (zh) * 2019-02-22 2021-09-21 清华大学 使用片段化模式确定血浆游离核酸分子组织来源的方法和系统及应用
WO2020198942A1 (zh) * 2019-03-29 2020-10-08 中国科学技术大学 基于峰聚类的单细胞染色质可及性测序数据分析方法和系统
EP3976822A1 (en) 2019-05-31 2022-04-06 Guardant Health, Inc. Methods and systems for improving patient monitoring after surgery
CN110272985B (zh) * 2019-06-26 2021-08-17 广州市雄基生物信息技术有限公司 基于外周血血浆游离dna高通量测序技术的肿瘤筛查试剂盒及其系统与方法
EP4041919A1 (en) 2019-09-30 2022-08-17 Guardant Health, Inc. Compositions and methods for analyzing cell-free dna in methylation partitioning assays
WO2021072275A1 (en) 2019-10-11 2021-04-15 Guardant Health, Inc. Use of cell free bacterial nucleic acids for detection of cancer
CN110739027B (zh) * 2019-10-23 2023-04-18 深圳吉因加医学检验实验室 一种基于染色质区域覆盖深度的癌症组织定位方法及系统
ES3031713T3 (en) 2019-11-26 2025-07-10 Guardant Health Inc Methods, compositions and systems for improving the binding of methylated polynucleotides
US20210189494A1 (en) * 2019-12-18 2021-06-24 The Chinese University Of Hong Kong Cell-free dna fragmentation and nucleases
WO2021126091A1 (en) * 2019-12-19 2021-06-24 Agency For Science, Technology And Research A method of estimating a circulating tumor dna burden and related kits and methods
EP4077735A4 (en) * 2019-12-20 2024-01-24 AccuraGen Holdings Limited METHOD AND SYSTEMS FOR DETECTING DISEASES
EP4081655B1 (en) 2019-12-24 2026-03-18 Vib Vzw Disease detection in liquid biopsies
US20210238668A1 (en) * 2020-01-08 2021-08-05 The Chinese University Of Hong Kong Biterminal dna fragment types in cell-free samples and uses thereof
WO2021141220A1 (ko) * 2020-01-09 2021-07-15 서울대학교 산학협력단 ATAC-seq 데이터 정규화 및 이의 활용 방법
CN111254194B (zh) * 2020-01-13 2021-09-07 东南大学 基于cfDNA的测序及数据分析的癌症相关生物标记及其在cfDNA样品分类中的应用
EP4104179B1 (en) * 2020-02-13 2026-01-28 10X Genomics, Inc. Systems and methods for joint interactive visualization of gene expression and dna chromatin accessibility
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
CN113362897A (zh) * 2020-03-06 2021-09-07 福建和瑞基因科技有限公司 基于核小体分布特征的肿瘤标志物筛选方法及应用
WO2021222828A1 (en) 2020-04-30 2021-11-04 Guardant Health, Inc. Methods for sequence determination using partitioned nucleic acids
WO2021236993A1 (en) 2020-05-22 2021-11-25 Bloodq, Inc. Methods for characterizing cell-free nucleic acid fragments
CN111724860B (zh) * 2020-06-18 2021-03-16 深圳吉因加医学检验实验室 一种基于测序数据识别染色质开放区域的方法及装置
EP4407042A3 (en) 2020-07-10 2024-09-18 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN111881418B (zh) * 2020-07-27 2023-05-16 中国农业科学院农业信息研究所 一种基于二分法的大豆气象产量预测方法及系统
ES3018032T3 (en) 2020-07-30 2025-05-14 Guardant Health Inc Methods for isolating cell-free dna
CN112085067B (zh) * 2020-08-17 2022-07-12 浙江大学 一种高通量筛选dna损伤反应抑制剂的方法
WO2022046947A1 (en) 2020-08-25 2022-03-03 Guardant Health, Inc. Methods and systems for predicting an origin of a variant
WO2022061080A1 (en) * 2020-09-17 2022-03-24 The Regents Of The University Of Colorado, A Body Corporate Signatures in cell-free dna to detect disease, track treatment response, and inform treatment decisions
JP2023544720A (ja) 2020-09-30 2023-10-25 ガーダント ヘルス， インコーポレイテッド Ｄｎａメチル化分配アッセイのシグナル対ノイズ比を改善するための方法およびシステム
WO2022087309A1 (en) 2020-10-23 2022-04-28 Guardant Health, Inc. Compositions and methods for analyzing dna using partitioning and base conversion
EP4251765A1 (en) 2020-11-30 2023-10-04 Guardant Health, Inc. Compositions and methods for enriching methylated polynucleotides
EP4267757A1 (en) 2020-12-23 2023-11-01 Guardant Health, Inc. Methods and systems for analyzing methylated polynucleotides
TW202242130A (zh) * 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242145A (zh) * 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
US20230175064A1 (en) * 2021-02-09 2023-06-08 Illumina, Inc. Methods and systems for monitoring organ health and disease
WO2022174109A1 (en) 2021-02-12 2022-08-18 Guardant Health, Inc. Methods and compositions for detecting nucleic acid variants
WO2022204730A1 (en) 2021-03-25 2022-09-29 Guardant Health, Inc. Methods and compositions for quantifying immune cell dna
WO2022216981A1 (en) * 2021-04-08 2022-10-13 Delfi Diagnostics, Inc. Method of detecting cancer using genome-wide cfdna fragmentation profiles
AU2022255198A1 (en) * 2021-04-08 2023-11-23 Fred Hutchinson Cancer Center Cell-free dna sequence data analysis method to examine nucleosome protection and chromatin accessibility
WO2022271730A1 (en) 2021-06-21 2022-12-29 Guardant Health, Inc. Methods and compositions for copy-number informed tissue-of-origin analysis
WO2023056065A1 (en) 2021-09-30 2023-04-06 Guardant Health, Inc. Compositions and methods for synthesis and use of probes targeting nucleic acid rearrangements
JP2025513786A (ja) 2022-04-07 2025-04-30 ガーダント ヘルス， インコーポレイテッド 無細胞核酸分子のメチル化状態に基づいた腫瘍の存在の検出
GB202205710D0 (en) 2022-04-19 2022-06-01 Univ Of Essex Enterprises Limited Cell-free DNA-based methods
JP2025522763A (ja) 2022-06-30 2025-07-17 ガーダント ヘルス， インコーポレイテッド 異常にメチル化されたｄｎａの富化
WO2024056720A1 (en) 2022-09-13 2024-03-21 Medizinische Universität Graz Determining of health status and treatment monitoring with cell-free dna
JP2025532196A (ja) 2022-09-27 2025-09-29 ガーダント ヘルス， インコーポレイテッド 免疫細胞ｄｎａを定量するための方法
WO2024138180A2 (en) 2022-12-22 2024-06-27 Guardant Health, Inc. Integrated targeted and whole genome somatic and dna methylation sequencing workflows
WO2024137880A2 (en) 2022-12-22 2024-06-27 Guardant Health, Inc. Methods involving methylation preserving amplification with error correction
WO2024233502A1 (en) 2023-05-05 2024-11-14 Guardant Health, Inc. Cell-free dna blood-based test for cancer screening
WO2025029475A1 (en) 2023-07-28 2025-02-06 Guardant Health, Inc. Methods to enrich nucleotide variants by negative selection
EP4758267A1 (en) 2023-08-11 2026-06-17 Guardant Health, Inc. Methylated enrichment methods for single-molecule genetic and epigenetic sequencing
CN117230165A (zh) * 2023-09-01 2023-12-15 深圳湾实验室 一种无创产前检测胎儿染色体拷贝数异常的优化方法
EP4781415A1 (en) 2023-09-19 2026-07-29 Guardant Health, Inc. Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules
WO2025076452A1 (en) 2023-10-06 2025-04-10 Guardant Health, Inc. Detecting tumor-related information based on methylation status of cell-free nucleic acid molecules
WO2025137389A2 (en) 2023-12-22 2025-06-26 Guardant Health, Inc. Methods for targeted single-molecule genetic and epigenetic sequencing
WO2025207817A1 (en) 2024-03-26 2025-10-02 Guardant Health, Inc. Method of determining the likelihood of a disease by combining biomarkers and imaging
WO2025208044A1 (en) 2024-03-28 2025-10-02 Guardant Health, Inc. Methods for cancer detection using molecular patterns
WO2025235889A1 (en) 2024-05-10 2025-11-13 Guardant Health, Inc. Methods involving multiplexed pooled pcr
WO2025250544A1 (en) 2024-05-31 2025-12-04 Guardant Health, Inc. Methods for analyzing chromatin architecture in tissue to boost detection of cancer associated signals in cell-free dna
WO2026015607A1 (en) 2024-07-09 2026-01-15 Guardant Health, Inc. Methods for partitioning hyper-, hypo-, and non-methylated dna
WO2026043718A1 (en) 2024-08-21 2026-02-26 Guardant Health, Inc. Methods to monitor patients treated with a cancer vaccine
WO2026060266A1 (en) 2024-09-13 2026-03-19 Guardant Health, Inc. Use of copy number variants for the identification of false positive tumor calls
WO2026073140A1 (en) 2024-09-27 2026-04-02 Guardant Health, Inc. Framework to identify genomic regions indicative of one or more biological conditions
WO2026076332A1 (en) 2024-10-03 2026-04-09 Guardant Health, Inc. Methods involving multi-modal tumor variant identification and tracking of tumor molecules
WO2026090570A1 (en) 2024-10-24 2026-04-30 Guardant Health, Inc. Detecting the presence of a biological condition based on a nucleic acid sample data analysis
WO2026107204A1 (en) 2024-11-14 2026-05-21 Guardant Health, Inc. Methods for analyzing low-depth genome sequencing data to detect minimal residual disease
WO2026136560A1 (en) 2024-12-17 2026-06-25 Guardant Health, Inc. Methods for cfdna methylation data modeling using transformer neural network architecture
WO2026165504A1 (en) 2025-01-31 2026-08-06 Guardant Health, Inc. Methods for detecting nucleic acids from cancer cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103236A2 (en) * 2010-02-18 2011-08-25 The Johns Hopkins University Personalized tumor biomarkers

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016742D0 (en) * 2000-07-10 2000-08-30 Simeg Limited Diagnostic method
JP2002272497A (ja) 2001-03-15 2002-09-24 Venture Link Co Ltd 癌の診断方法、およびその診断用ベクター
US6927028B2 (en) 2001-08-31 2005-08-09 Chinese University Of Hong Kong Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA
EP1599608A4 (en) 2003-03-05 2007-07-18 Genetic Technologies Ltd Identification of fetal DNA and fetal cell marker in maternal plasma or serum
DE60328193D1 (de) 2003-10-16 2009-08-13 Sequenom Inc Nicht invasiver Nachweis fötaler genetischer Merkmale
US20070122823A1 (en) 2005-09-01 2007-05-31 Bianchi Diana W Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis
WO2007092473A2 (en) 2006-02-02 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive fetal genetic screening by digital analysis
SI1996728T1 (sl) 2006-02-28 2011-10-28 Univ Louisville Res Found Prepoznavanje kromosomskih nenormalnosti pri zarodku s pomočjo dvojnih mononukleotidnih polimorfizmov
CN101153336B (zh) 2006-09-27 2011-09-07 香港中文大学 检测dna甲基化程度的方法和试剂盒
US7842482B2 (en) 2007-02-26 2010-11-30 The Chinese University Of Hong Kong Methods and kits for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer
US12180549B2 (en) 2007-07-23 2024-12-31 The Chinese University Of Hong Kong Diagnosing fetal chromosomal aneuploidy using genomic sequencing
US12054776B2 (en) 2007-07-23 2024-08-06 The Chinese University Of Hong Kong Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
US8748100B2 (en) 2007-08-30 2014-06-10 The Chinese University Of Hong Kong Methods and kits for selectively amplifying, detecting or quantifying target DNA with specific end sequences
WO2009051842A2 (en) 2007-10-18 2009-04-23 The Johns Hopkins University Detection of cancer by measuring genomic copy number and strand length in cell-free dna
US20100041048A1 (en) 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
US8476013B2 (en) * 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
WO2010033578A2 (en) 2008-09-20 2010-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
WO2010053980A2 (en) 2008-11-04 2010-05-14 The Johns Hopkins University Dna integrity assay (dia) for cancer diagnostics, using confocal fluorescence spectroscopy
US20120021428A1 (en) 2009-03-31 2012-01-26 Marcus Otte Method for diagnosis of cancer and monitoring of cancer treatments
EP2494065B1 (en) * 2009-10-26 2015-12-23 Lifecodexx AG Means and methods for non-invasive diagnosis of chromosomal aneuploidy
WO2011053790A2 (en) 2009-10-30 2011-05-05 Fluidigm Corporation Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis
LT3241914T (lt) 2009-11-05 2019-04-25 The Chinese University Of Hong Kong Vaisiaus genomo analizė iš motinos biologinio mėginio
CA2780016C (en) 2009-11-06 2017-09-19 The Chinese University Of Hong Kong Size-based genomic analysis
DK2496720T3 (da) * 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
US20120010085A1 (en) 2010-01-19 2012-01-12 Rava Richard P Methods for determining fraction of fetal nucleic acids in maternal samples
US9260745B2 (en) 2010-01-19 2016-02-16 Verinata Health, Inc. Detecting and classifying copy number variation
US10047397B2 (en) * 2010-04-16 2018-08-14 Chronix Biomedical Breast cancer associated circulating nucleic acid biomarkers
EP2854058A3 (en) * 2010-05-18 2015-10-28 Natera, Inc. Methods for non-invasive pre-natal ploidy calling
EP2596127A2 (en) * 2010-07-23 2013-05-29 Esoterix Genetic Laboratories, LLC Identification of differentially represented fetal or maternal genomic regions and uses thereof
US10167508B2 (en) * 2010-08-06 2019-01-01 Ariosa Diagnostics, Inc. Detection of genetic abnormalities
WO2012027483A2 (en) * 2010-08-24 2012-03-01 Bio Dx, Inc. Defining diagnostic and therapeutic targets of conserved free floating fetal dna in maternal circulating blood
EP2426217A1 (en) 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
KR102040307B1 (ko) 2010-11-30 2019-11-27 더 차이니즈 유니버시티 오브 홍콩 암과 연관된 유전적 또는 분자적 이상들의 검출
CA3069089A1 (en) 2011-09-22 2013-03-28 Lineage Biosciences, Inc. Compositions and methods for analyzing heterogeneous samples
US10196681B2 (en) 2011-10-06 2019-02-05 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2013060762A1 (en) 2011-10-25 2013-05-02 Roche Diagnostics Gmbh Method for diagnosing a disease based on plasma-dna distribution
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP3584327A1 (en) 2012-01-27 2019-12-25 The Board of Trustees of the Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
EP4155401A1 (en) * 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
AU2013232123B2 (en) 2012-03-13 2014-10-30 The Chinese University Of Hong Kong Methods for analyzing massively parallel sequencing data for noninvasive prenatal diagnosis
EP4276194B1 (en) * 2012-05-21 2026-08-05 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2013177581A2 (en) * 2012-05-24 2013-11-28 University Of Washington Through Its Center For Commercialization Whole genome sequencing of a human fetus
US11261494B2 (en) * 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
PL2893040T3 (pl) 2012-09-04 2019-05-31 Guardant Health Inc Sposoby wykrywania rzadkich mutacji i wariantu liczby kopii
US20160004814A1 (en) * 2012-09-05 2016-01-07 University Of Washington Through Its Center For Commercialization Methods and compositions related to regulation of nucleic acids
US9732390B2 (en) 2012-09-20 2017-08-15 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
HUE053822T2 (hu) 2012-09-20 2021-07-28 Univ Hong Kong Chinese Nem invazív módszer daganat metilom meghatározása plazmából
AU2014268377B2 (en) * 2013-05-24 2020-10-08 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
PL3004388T5 (pl) * 2013-05-29 2023-10-09 Chronix Biomedical Wykrywanie i oznaczanie ilościowe pozakomórkowego dna dawcy w układzie krążenia biorców przeszczepów organów
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
RU2717641C2 (ru) * 2014-04-21 2020-03-24 Натера, Инк. Обнаружение мутаций и плоидности в хромосомных сегментах
WO2015184404A1 (en) * 2014-05-30 2015-12-03 Verinata Health, Inc. Detecting fetal sub-chromosomal aneuploidies and copy number variations
TWI758011B (zh) 2014-07-18 2022-03-11 香港中文大學 Ｄｎａ混合物中之組織甲基化模式分析
CN107002122B (zh) 2014-07-25 2023-09-19 华盛顿大学 确定导致无细胞dna的产生的组织和/或细胞类型的方法以及使用其鉴定疾病或紊乱的方法
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US11242559B2 (en) 2015-01-13 2022-02-08 The Chinese University Of Hong Kong Method of nuclear DNA and mitochondrial DNA analysis
US10319463B2 (en) 2015-01-23 2019-06-11 The Chinese University Of Hong Kong Combined size- and count-based analysis of maternal plasma for detection of fetal subchromosomal aberrations
DK3256605T3 (da) 2015-02-10 2022-03-14 Univ Hong Kong Chinese Påvisning af mutationer til cancerscreening og føtal analyse
US10453556B2 (en) 2015-07-23 2019-10-22 The Chinese University Of Hong Kong Analysis of fragmentation patterns of cell-free DNA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103236A2 (en) * 2010-02-18 2011-08-25 The Johns Hopkins University Personalized tumor biomarkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BMC MEDICAL GENOMICS, vol. Vol. 8, 29, JPN6019022612, 17 June 2015 (2015-06-17), ISSN: 0004274441 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531016A (ja) * 2018-07-23 2021-11-18 ザ チャイニーズ ユニバーシティ オブ ホンコン 無細胞ｄｎａ損傷分析およびその臨床応用
JP2024112999A (ja) * 2018-07-23 2024-08-21 ザ チャイニーズ ユニバーシティ オブ ホンコン 無細胞ｄｎａ損傷分析およびその臨床応用
JP2022517456A (ja) * 2019-01-24 2022-03-09 イルミナ インコーポレイテッド 臓器健康および疾患をモニタリングするための方法およびシステム

Also Published As

Publication number Publication date
KR102441391B1 (ko) 2022-09-07
AU2022202587B2 (en) 2024-07-04
EP3172341A4 (en) 2018-03-28
EP3172341A2 (en) 2017-05-31
US20210010081A1 (en) 2021-01-14
US20190127794A1 (en) 2019-05-02
CN107002122A (zh) 2017-08-01
AU2022202587A1 (en) 2022-05-26
US11352670B2 (en) 2022-06-07
AU2015292311B2 (en) 2022-01-20
JP2021045161A (ja) 2021-03-25
KR20220127359A (ko) 2022-09-19
CN117402950A (zh) 2024-01-16
KR102696857B1 (ko) 2024-08-19
AU2015292311A1 (en) 2017-03-09
CN107002122B (zh) 2023-09-19
CA2956208A1 (en) 2016-01-28
EP4358097A1 (en) 2024-04-24
WO2016015058A2 (en) 2016-01-28
US20230212672A1 (en) 2023-07-06
JP2023123420A (ja) 2023-09-05
CA2956208C (en) 2025-07-08
KR20170044660A (ko) 2017-04-25
US20170211143A1 (en) 2017-07-27
WO2016015058A3 (en) 2016-03-17
JP7681641B2 (ja) 2025-05-22

Similar Documents

Publication Publication Date Title
JP7681641B2 (ja) セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法
Snyder et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin
AU2019263869B2 (en) Size-tagged preferred ends and orientation-aware analysis for measuring properties of cell-free mixtures
EP3765017B1 (en) Methods using nucleic acid signals for revealing biological attributes
EP3526350B1 (en) Determining cell type origin of circulating cell-free dna with molecular counting
EP3555311B1 (en) Determining a physiological condition in an individual by analyzing cell-free dna fragment endpoints in a biological sample
CN119546781A (zh) 无细胞dna的表观遗传学分析
US20200255905A1 (en) Diagnosis of cancer or other physiological condition using circulating nucleic acid fragment sentinel endpoints
Caggiano et al. Epigenetic profiles of tissue informative CpGs inform ALS disease status and progression
HK40110787A (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
Zhou Fragmentomic and Epigenetic Analyses for Cell-Free DNA Molecules
Doebley Predicting cancer subtypes from nucleosome profiling of cell-free DNA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210304